Weekly 52-Week Highs: NEE, CCE, LOW, NXY, VRX

Author's Avatar
Feb 11, 2013
Weekly 52-Week Highs: NexEra Energy Inc. (NEE, Financial), Coca-Cola Enterprises Inc. (CCE, Financial), Lowe’s Companies Inc. (LOW, Financial), Nexen Inc. (NXY, Financial) and Valeant Pharmaceutical International Inc. (VRX, Financial).

NextEra Energy Inc. (NEE) Reached the 52-Week High of $72.03


The prices of NextEra Energy Inc. shares have reached $72.03, which is 1.2% off the 52-week high of $72.87. NextEra Energy Inc. was incorporated in 1984 under the laws of Florida. NextEra Energy Inc. has a market cap of $30.51 billion; its shares were traded at around $72.03 with a P/E ratio of 14.0252 and P/S ratio of 2.0446. The dividend yield of NextEra Energy Inc. stocks is 3.33%. NextEra Energy Inc. had an annual average earnings growth of 8.6% over the past 10 years.

On Oct. 24, NextEra Energy Inc. reported 2012 third quarter net income on a GAAP basis of $415 million, or $0.98 per share, compared with $407 million, or $0.97 per share, in the third quarter of 2011. On an adjusted basis, NextEra Energy’s earnings were $532 million, or $1.26 per share, compared with $551 million, or $1.31 per share, in the third quarter of 2011.

In October, Director William H. Swanson bought 7,195 shares of NEE stock. Treasurer of Sub Paul I. Cutler sold 22,000 shares in December. Director, Executive Vice President Power Gen. of Sub Antonio Rodriguez, Director and President of Sub Eric E. Silagy, and Director and CEO of Sub James L. Robo sold shares in November. Director of Sub Lewis Hay III sold 150,000 shares in October.



Coca-Cola Enterprises Inc. (CCE) Reached the 52-Week High of $35.35


The prices of Coca-Cola Enterprises Inc. shares have reached $35.35, which is 1.2% off the 52-week high of $35.79. Coca-Cola Enterprises Inc. completed a merger with TCCC and separated its European operations, Coca-Cola Enterprises (Canada) Bottling Finance Company, and a related portion of its corporate segment into a new legal entity which was renamed Coca-Cola Enterprises Inc. Coca-Cola Enterprises Inc. has a market cap of $10.16 billion; its shares were traded at around $35.35 with a P/E ratio of 15.7233 and P/S ratio of 1.3504. The dividend yield of Coca-Cola Enterprises Inc. stocks is 1.81%.

On Feb. 7, Coca-Cola Enterprises Inc. reported full-year 2012 earnings per diluted share of $2.25, or $2.26 on a comparable basis. Reported operating income for the year totaled $928 million; comparable operating income totaled $1.0 billion, up 2½% on a comparable and currency neutral basis versus a year ago.

This month, Senior Vice President, General Counsel John R. Parker Jr. and Executive Vice President and CFO William W. Douglas III sold shares of CCE stock. Vice President, Controller and CAO Suzanne D. Patterson sold 26,755 in November and Chairman and CEO John Brock sold shares in September.

Lowe's Companies Inc. (LOW) Reached the 52-Week High of $38.98

The prices of Lowe's Companies Inc. shares have reached $38.98, which is 0.7% off the 52-week high of $39.26. Lowe's Companies, Inc. was incorporated in North Carolina in 1952 and has been publicly held since 1961. Lowe's Companies Inc. has a market cap of $43.9 billion; its shares were traded at around $38.98 with a P/E ratio of 23.1481 and P/S ratio of 0.9029. The dividend yield of Lowe's Companies Inc. stocks is 1.59%. Lowe's Companies Inc. had an annual average earnings growth of 5.6% over the past 10 years.

On Nov. 19, Lowe’s Companies Inc. reported net earnings of $396 million for the quarter ended November 2, 2012, a 76.0 percent increase over the same period a year ago. Diluted earnings per share increased 94.4 percent to $0.35. For the nine months ended Nov. 2, 2012, net earnings increased 10.1 percent from the same period a year ago to $1.67 billion, while diluted earnings per share increased 21.4 percent to $1.42.

Last month, COO Ricky D. Damron sold 23,367 shares of LOW stock. Chief Human Resources Officer Maureen K. Ausura, Chief Customer Officer Gregory M. Bridgeford, Director Peter C. Browning and CFO Robert F. Hull Jr. sold shares in December. CLO, CCO and Secretary Gaither M. Keener Jr. and Chairman, President and CEO Robert A. Niblock sold shares in November.

Nexen Inc. (NXY) Reached the 52-Week High of $26.81

The prices of Nexen Inc. shares have reached $26.81, which is 0.9% off the 52-week high of $27.06. Nexen Inc. was formed in Canada in 1971. It is an independent global energy company. Nexen Inc. has a market cap of $14.26 billion; its shares were traded at around $26.81 with a P/E ratio of 38.61 and P/S ratio of 2.1983. The dividend yield of Nexen Inc. stocks is 0.74%.

On October 25, Nexen Inc. reported third quarter operating and financial results and provided an update on strategic priorities. Production volumes averaged 181,000 barrels of oil equivalent per day (boe/d), a decrease from second quarter production of 213,000 boe/d. Cash flow from operations decreased to $560 million ($1.06 per share) from $707 million ($1.34 per share) in the second quarter, primarily due to the lower production and higher operating costs associated with the planned turnarounds. Net income decreased to $59 million ($0.11 per share) from $109 million ($0.20 per share) in the second quarter.

Valeant Pharmaceuticals International Inc. (VRX) Reached the 52-Week High of $67.72

The prices of Valeant Pharmaceuticals International Inc. shares have reached $67.72, which is 0.4% off the 52-week high of $67.98. Valeant Pharmaceuticals International Inc. was formerly known as Biovail Corporation. Valeant Pharmaceuticals International Inc. has a market cap of $20.67 billion; its shares were traded at around $67.72 with a P/E ratio of 714.286 and P/S ratio of 6.4392. Valeant Pharmaceuticals International Inc. had an annual average earnings growth of 1.3% over the past 10 years.

On Nov. 2, Valeant Pharmaceuticals International Inc. announced third quarter financial results for 2012. The company reported net income of $7.6 million for the third quarter of 2012, or $0.02 per diluted share. On a cash EPS basis, adjusted income was $357.5 million, or $1.15 per diluted share.

In November, Executive Vice President and CFO Howard Bradley Schiller, Director Lloyd Mitchell Segal, Executive Vice President, Administration and CHCO Brian M. Stolz and President and COO, Specialty Pharm Silva Rajiv De sold shares of VRX stock.